Lumasiran Sodium Patent Expiration
Lumasiran Sodium is Used for treating primary hyperoxaluria type 1 (PH1). It was first introduced by Alnylam Pharmaceuticals Inc
Lumasiran Sodium Patents
Given below is the list of patents protecting Lumasiran Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Oxlumo | US11261447 | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | Nov 20, 2038 | Alnylam Pharms Inc |
| Oxlumo | US10478500 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | Oct 09, 2035 | Alnylam Pharms Inc |
| Oxlumo | US11446380 | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | Oct 09, 2035 | Alnylam Pharms Inc |
| Oxlumo | US10612024 | Modified double-stranded RNA agents | Aug 14, 2035 | Alnylam Pharms Inc |
| Oxlumo | US10612027 | Modified double-stranded RNA agents | Aug 14, 2035 | Alnylam Pharms Inc |
| Oxlumo | US11401517 | Modified double-stranded RNA agents | Aug 14, 2035 | Alnylam Pharms Inc |
| Oxlumo | US10435692 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | Dec 26, 2034 | Alnylam Pharms Inc |
| Oxlumo | US10465195 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | Dec 26, 2034 | Alnylam Pharms Inc |
| Oxlumo | US10487330 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | Dec 26, 2034 | Alnylam Pharms Inc |
| Oxlumo | US11060093 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | Dec 26, 2034 | Alnylam Pharms Inc |
| Oxlumo | US9828606 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | Dec 26, 2034 | Alnylam Pharms Inc |
| Oxlumo | US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 12, 2029 | Alnylam Pharms Inc |
| Oxlumo | US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Alnylam Pharms Inc |
| Oxlumo | US10131907 | Glycoconjugates of RNA interference agents | Aug 24, 2028 | Alnylam Pharms Inc |
Lumasiran Sodium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List